• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Adverse events following COVID ‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
ConclusionAvailable literature includes more studies with the BNT162b2 vaccine than mRNA-1273. Future studies must report mortality and adverse cardiovascular events by vaccine types.
Source: Immunity, Inflammation and Disease - March 17, 2023 Category: Allergy & Immunology Authors: Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Abdul Raafe Atif, Muhammad Sohaib Asghar, Nayef Nimri, Maryam Saleem, Dhrubajyoti Bandyopadhyay, Chayakrit Krittanawong, Mohammed Mahmmoud Fadelallah Eljack, Muhammad Junaid Tahir, Fahad Wa Tags: REVIEW ARTICLE Source Type: research

A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan
CONCLUSION: The findings suggested that the COVID-19 mRNA vaccine was generally safe, whilst a signal of pulmonary embolism following the first dose of the COVID-19 mRNA vaccine was observed.PMID:36371366 | DOI:10.1016/j.vaccine.2022.10.088
Source: Vaccine - November 12, 2022 Category: Allergy & Immunology Authors: Yoshinori Takeuchi Masao Iwagami Sachiko Ono Nobuaki Michihata Kohei Uemura Hideo Yasunaga Source Type: research

Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.PMID:35667917 | PMC:PMC9163997 | DOI:10.1016/j.vaccine.2022.05.075
Source: Vaccine - June 6, 2022 Category: Allergy & Immunology Authors: Norazida Ab Rahman Ming Tsuey Lim Fei Yee Lee Sing Chet Lee Azuana Ramli Siti Nurhafizah Saharudin Teck Long King Emelyne Bani Anak Jam Nor Aliya Ayub Raj Kumar Sevalingam Rashidah Bahari Nor Nadziroh Ibrahim Fatihah Mahmud Sheamini Sivasampu Kalaiarasu M Source Type: research

Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic Thrombocytopenia
In conclusion, insufficient resolution of NETs, e.g. by endogenous DNases or protection of NETs against degradation by embedded factors like the antimicrobial peptide LL-37 might thus be an important factor in the pathology of VITT besides increased NET-formation. On the basis of these findings, we discuss the potential implications of the mechanisms of disturbed NETs-degradation for diagnostic and therapeutic approaches in VITT-related thrombogenesis, other auto-immune disorders and beyond.
Source: Frontiers in Immunology - May 10, 2022 Category: Allergy & Immunology Source Type: research

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data
In conclusion, both virus-based COVID-19 vaccines show more SAEs than BNT, but the frequency of the SAE type in the different age groups differs, suggesting that the mechanisms responsible of SAEs overlap only partly.PMID:34710832 | PMC:PMC8547775 | DOI:10.1016/j.jaut.2021.102742
Source: Journal of Autoimmunity - October 28, 2021 Category: Allergy & Immunology Authors: Luigi Cari Mahdieh Naghavi Alhosseini Paolo Fiore Sabata Pierno Sabrina Pacor Alberta Bergamo Gianni Sava Giuseppe Nocentini Source Type: research

Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome
In conclusion the detection of complement activation products on circulating erythrocytes and platelets using a highly sensitive and specific assay further supports the view that APS is a complement-mediated disorder. Increased EC4d and PC4d percentages are associated with the active inflammatory disease in SLE. It is difficult to translate this finding to APS which is a non-acute inflammatory disorder. We failed to find an association with both the classification and non-classification criteria, including thrombocytopenia. However, we believe that this sensitive tool to evaluate complement activation may offer more inform...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment
AbstractDeficiency of ADA2 (DADA2) is the first molecularly described monogenic vasculitis syndrome. DADA2 is caused by biallelic hypomorphic mutations in theADA2 gene that encodes the adenosine deaminase 2 (ADA2) protein. Over 60 disease-associated mutations have been identified in all domains of ADA2 affecting the catalytic activity, protein dimerization, and secretion. Vasculopathy ranging from livedo reticularis to polyarteritis nodosa (PAN) and life-threatening ischemic and/or hemorrhagic stroke dominate the clinical features of DADA2. Vasculitis and inflammation can affect many organs, explaining the intestinal, hepa...
Source: Journal of Clinical Immunology - June 27, 2018 Category: Allergy & Immunology Source Type: research

Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence
Conclusions This study suggest, that in primary APS, persistent negative aPL profile is not an indication to interrupt oral anticoagulant therapy. However, there is a subset of patients that remained asymptomatic. Other studies are necessary in order to elucidate this controversy.
Source: Autoimmunity Reviews - February 12, 2017 Category: Allergy & Immunology Source Type: research

Diagnosis and classification of the antiphospholipid syndrome.
Abstract The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial thromboses, often multiple, and recurrent fetal losses, frequently accompanied by a moderate thrombocytopenia, in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. The orig...
Source: Journal of Autoimmunity - January 22, 2014 Category: Allergy & Immunology Authors: Gómez-Puerta JA, Cervera R Tags: J Autoimmun Source Type: research